肌肉减少症是一种骨骼肌疾病,通常随着年龄的增长以及许多长期疾病而发生。临床实践中的认识相对较新,但很重要,因为肌肉减少症与一系列对健康的不利影响(包括行动不便)之间存在关联。发病率和死亡率增加。最初以肌肉质量损失为特征,这个定义已经发展到关注骨骼肌功能的丧失,特别是力量,通过许多国际定义,例如欧洲老年人肌肉减少症工作组的定义,最近于2019年修订。在使用常规健康数据方面,未来几十年可能会取得进展。抗阻运动的处方,将生物学和流行病学转化为人类研究新疗法的第一,关注中低收入国家的肌肉减少症。接下来的步骤包括新成立的全球肌肉减少症领导力倡议,以就定义和诊断达成国际共识。
Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international
consensus on definition and diagnosis.